Navigation Links
Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
Date:2/5/2009

ibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 ... equities: Genetic Technologies Ltd (NASDAQ: GENE ), ... Fisher Scientific Inc. (NYSE: TMO ), Sequenom ... (NYSE: PKI ). Free research report on ... . On Thursday, April 30, 2015, the NASDAQ ...
(Date:5/1/2015)... and RESEARCH TRIANGLE PARK, N.C. , May ... announced today that Roger Jeffs , Ph.D., President and ... and update on the company,s business at the Deutsche Bank ... Boston, Massachusetts . The presentation will take ... Time, and can be accessed via a live webcast on ...
(Date:4/30/2015)... 2015   Tamir Biotechnology , a leading developer ... its Ebola antiviral therapy program. Clinical ... currently being evaluated and considered by a number of ... During the first quarter of 2015, the company participated ... The Evaluation of Potential Treatments and Vaccines For Ebola ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology ... capacity and production capability to serve biotechnology pharmaceutical ... service fulfillment continues to drive Nitto Avecia to ... capacities. , In Fall 2014, Nitto ... equipment at its Milford, MA facility, which is ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... Robotics today announced,that the European Union (EU) ... results of the SafeChemo Project it sponsored ... objectives were to scientifically and,independently establish if ... system for the safe preparation of hazardous ...
... Jan. 5 Baxter,International Inc. and Halozyme Therapeutics, ... start of a Phase III clinical trial of ... as KIOVIG in the European,Union, with Halozyme,s recombinant ... of primary immunodeficiency (PID).,The purpose of this clinical ...
... BMP Sunstone,Corporation (Nasdaq: BJGP ) ("BMP ... Pharmaceutical Co., Ltd., has been granted high tech,status ... is awarded by the PRC to,recognize companies that ... revenues generated by their own proprietary patented or,innovative ...
Cached Biology Technology:Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 2Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 3Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 4Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 2Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 3Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 4Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 5BMP Sunstone Receives High Tech Status 2BMP Sunstone Receives High Tech Status 3
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
(Date:3/18/2015)... , March 18, 2015 As mobile ... new revolutionary smart wallets and apps continue to be introduced ... entrenched in the mobile payment industry in focus today are:  ... Ltd. (NYSE: BABA ), Apple Inc. (NASDAQ: ... and Facebook Inc. (NASDAQ: FB ) ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... Park, MD (July 27, 2010) -- Drug delivery inside ... a maze of aqueous solutions, lipid membranes, and barriers ... reported in the American Institute of Physics publication the ... model that accurately predicts the hydration free energy (HFE) ...
... Park, MD (July 27, 2010) -- Fluids experts writing ... is published by the American Institute of Physics, are ... accurately probe the properties of turbulence near walls. High-Reynolds-number ... in aeronautics, naval applications, energy conversion processes, manufacturing, mixing ...
... fish scientist has received the Robert H. Gibbs, Jr. ... knowledge of fish diversity. The honor to Dr. ... the Ichthyology Department, was announced earlier this month in ... Society of Ichthyologists and Herpetologists. The Gibbs award is ...
Cached Biology News:
...
...
... Zero Blunt TOPO PCR Cloning Kit ... for high-efficiency (>=95%) cloning of blunt-end ... polymerases. The kit includes the linearized ... for 5-minute bench-top ligations without ligase ...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: